Business Wire

IL-NIQ

7.2.2024 13:01:35 CET | Business Wire | Press release

Share
NIQ Unveils Comprehensive 2024 Consumer Outlook Report: Navigating Global Trends and Insights for Strategic Growth

NIQ, a leading authority in consumer intelligence, proudly announces the release of its highly anticipated 2024 Global Consumer Outlook Report. This comprehensive document explores critical trends and insights that shape the consumer landscape, delivering invaluable data and analysis for businesses and stakeholders worldwide.

Navigating the intricate global economic terrain, the report delves into the repercussions of significant economic events and trends, shedding light on their impact on consumer confidence and spending behavior. Moving beyond a broad overview, the analysis explores regional variances, providing in-depth insights into the unique dynamics of Asia Pacific, Europe, North America, Africa, the Middle East, and Latin America. This bi-annual thought leadership study uncovers nuances in consumer preferences and changes in consumer attitudes and purchasing patterns, empowering retailers and manufacturers with a strategic understanding of their target markets to facilitate the formulation of tailored strategies for sustainable growth.

"In today's disruptive global economy, our Consumer Outlook Report for 2024 serves as a compass, navigating through the ripples of economic events and unveiling insights into consumer behavior,” said Tracey Massey, COO of NIQ. “As businesses confront the challenges of a changing landscape, this report equips them with strategic foresight, offering a tailored understanding of regional variances and empowering them to steer their course toward sustainable growth."

Key findings from the NIQ Global Consumer Outlook Report:

  • Value and Volume Slowdown: In November 2023, prices rose by 6.1%, a significant drop from the 13.6% increase observed in January 2023. As inflation decelerates, it reveals that the slowed growth in sales value no longer masks low or declining consumption rates. Retailers and brands must strategically respond to avert excessive promotions and safeguard the bottom line.
  • Consumers Under Pressure: Today, 34% of global consumers feel worse off financially than a year ago, as the unemployment rate remains steady and wages lag inflation. As the global crisis remains top-of-mind, expect increased competition for a smaller share of consumer spending.
  • Proactive and Precise with Wellness: 40% of global consumers proactively prioritize their health, contributing to a growth niche in the market. Recognizing the significance of proactive health management, consumers are keen on specific lifestyle changes and product features to attain their health goals.
  • Hybrid Views on Value: In a custom analysis across different price tiers, value-priced products were the only group to see sales share growth (0.6 pts) in 2023. Financial polarization between affluent and vulnerable consumers drives an expanded search for value options, and retailers and manufacturers should anticipate demand for new affordable product assortments in 2024.
  • Value-focused Innovation Growth: Manufacturers that innovate are 1.8 times more likely to boost overall sales. Continuous innovation has proven most advantageous for companies amid market slowdowns. Innovation isn't limited to premium positioning; companies must pursue value-driven initiatives to thrive.
  • Fluid Channel Dynamics: 11% of global consumers report shopping through social media channels. As the retail landscape evolves, adapting to changing patterns in how consumers explore, experiment with, and purchase products is crucial.

"The Global Consumer Outlook Report illuminates not just trends but critical shifts in consumer preferences and buying patterns, transcending borders and encompassing regions from North America to Asia Pacific,” said Lauren Fernandes, Global Director of Thought Leadership, NIQ. “From the ebb and flow of value and volume to the hybrid views on value, this report provides businesses with a comprehensive toolkit to adapt, innovate, and thrive in an environment marked by change. It's not just a report; it's a guide for businesses seeking resilience and relevance in an ever-shifting market."

NIQ’s commitment to delivering actionable insights is evident in the research and analysis presented in the Consumer Outlook Report. This valuable resource empowers businesses to make informed decisions in an ever-evolving consumer landscape. Download the report today.

About NIQ

NIQ is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. In 2023, NIQ combined with GfK, bringing together the two industry leaders with unparalleled global reach. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full ViewTM.

NIQ is an Advent International portfolio company with operations in 100+ markets, covering more than 90% of the world’s population. For more information, visit NIQ.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240207415974/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye